Purchase Order 75N93023P01241
Award Date 9/7/23
Potential Completion Date 9/28/24
Potential Value $12K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award to Genscript USA Inc. is for $182,897.61 to provide custom gene synthesis services to the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is a firm fixed-price purchase order with no set-aside designation, and the services include DNA synthesis, subcloning, and plasmid preparation to support HIV research being conducted at the NIH...
- Genscript USA Incorporated will provide gene synthesis services to the National Institutes of Health's National Institute of Allergy and Infectious Diseases under a $12,500 firm fixed price purchase order. The one-year contract was awarded on September 14, 2023 and runs through September 13, 2024. Genscript will deliver the gene synthesis work from its location in Piscataway, New Jersey. No subcontractors or additional context were provided regarding the specific research being supported under...
- This firm fixed-price purchase order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $3,943.72 contract is for custom gene synthesis services to support NIAID's biomedical research programs. Genscript, a for-profit organization, has a strong track record of providing specialized molecular biology products and services to...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Genscript USA Inc., a biotechnology company, for gene synthesis services. The $17,000.35 contract has a completion date of December 30, 2020 and was awarded on December 31, 2019. The services provided under this contract supported biomedical research and public health initiatives carried out by the agency. Genscript has...
- This federal contract award to Genscript USA Inc., a biotechnology company based in New Jersey, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $4,196.16 firm fixed-price purchase order is for gene synthesis services. Genscript, a for-profit organization, has a history of providing a wide range of molecular biology products and services to...
- The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $20,000 firm fixed price purchase order to Genscript USA Inc. to provide custom gene synthesis services. The contract will support NIH's research efforts at its Bethesda, Maryland campus through December 31, 2023. Genscript will deliver custom gene synthesis products to NIH researchers as part of the Institute's work to advance understanding of diseases...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $17,709 purchase order to Genscript USA Inc. to provide custom gene synthesis and expression services in support of its research efforts. The firm fixed price contract has a period of performance from September 18, 2023 through December 31, 2023 and will be carried out by Genscript at its facility located in Bethesda, Maryland. No major subcontractors or set aside designations were identified....
- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $37,889.60 firm fixed-price purchase order contract to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey, for custom gene synthesis and expression services. This requirement was sole-sourced to Genscript due to their specialized expertise in producing the specific gene constructs needed to support NIAID's vaccine research and development efforts. The contract...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $250,000 firm fixed price purchase order to Genscript USA Inc. of Piscataway, New Jersey. The order is for gene production and protein expression services to support the agency's research efforts. Services include gene synthesis, cloning, plasmid preparation, and protein expression and purification. The sole source award was negotiated under the authority of 41 U.S.C. 1901(a)(1) based on...
- This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $4,833.25 contract is for custom gene synthesis services to support NIAID's biomedical research and public health initiatives. While the award does not have a set-aside designation, Genscript has previously received some small business...
Genscript USA Incorporated will provide gene synthesis and vector ark cloning services to the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). Under the terms of a $12,108 firm fixed price purchase order, Genscript will deliver the requested products and services between September 2023 and September 2024. As the prime contractor, Genscript will leverage its expertise in gene synthesis and cloning to support NIAID's research efforts aimed at better understanding, treating, and preventing infectious diseases of high public health significance.
Generated 12/24/23, 3:55 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.1k | 9/7/23 |